CareDx (NASDAQ:CDNA - Get Free Report) released its earnings results on Wednesday. The company reported $1.51 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $1.46, Zacks reports. The company had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%.
CareDx Price Performance
CareDx stock traded up $1.09 during trading hours on Friday, reaching $22.15. The company had a trading volume of 1,300,838 shares, compared to its average volume of 841,652. CareDx has a 12-month low of $7.42 and a 12-month high of $34.84. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -8.20 and a beta of 1.87. The company has a 50-day moving average price of $22.69 and a 200 day moving average price of $25.21.
Analyst Ratings Changes
A number of analysts recently weighed in on CDNA shares. StockNews.com upgraded CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday. Wells Fargo & Company upgraded CareDx from an "underweight" rating to an "equal weight" rating and dropped their target price for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th. BTIG Research dropped their target price on CareDx from $40.00 to $35.00 and set a "buy" rating for the company in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a "neutral" rating and issued a $26.00 price target on shares of CareDx in a research note on Tuesday, January 14th. Finally, Stephens reaffirmed an "overweight" rating and issued a $40.00 price target on shares of CareDx in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, CareDx presently has a consensus rating of "Moderate Buy" and an average target price of $32.00.
Check Out Our Latest Analysis on CareDx
About CareDx
(
Get Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Read More
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
